These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9841457)

  • 1. [The pharmacological and clinical outlook for mibefradil--a new selective T-type calcium channel antagonist].
    Eliseev OM
    Ter Arkh; 1998; 70(8):87-8. PubMed ID: 9841457
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacologic and clinical perspectives on mibefradil: a new T-channel selective calcium antagonist: introduction.
    Giles TD
    Am J Cardiol; 1997 Aug; 80(4B):1C-3C. PubMed ID: 9286847
    [No Abstract]   [Full Text] [Related]  

  • 3. [Introducing mibefradil--a new T-calcium channel blocker].
    Internist (Berl); 1997 Dec; 38(12 Suppl Mibefradil):1-4. PubMed ID: 9437250
    [No Abstract]   [Full Text] [Related]  

  • 4. [Mibefradil: a new class calcium inhibitor].
    Internist (Berl); 1996 Oct; 37(10 Suppl Mibefradil):1-8. PubMed ID: 9402420
    [No Abstract]   [Full Text] [Related]  

  • 5. [Mibefradil opens up a new class of calcium antagonists. Glasgow, 23 June 1996].
    Dtsch Med Wochenschr; 1996 Sep; 121(39 Suppl):1-4. PubMed ID: 9212757
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist.
    Triggle DJ
    Am J Cardiol; 1996 Nov; 78(9A):7-12. PubMed ID: 8903279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mibefradil: a new twist to the calcium channel antagonist.
    Lynn MM
    Nurse Pract; 1998 May; 23(5):100, 102-4, 106-7. PubMed ID: 9614683
    [No Abstract]   [Full Text] [Related]  

  • 8. Rhabdomyolysis due to interaction of simvastatin with mibefradil.
    Schmassmann-Suhijar D; Bullingham R; Gasser R; Schmutz J; Haefeli WE
    Lancet; 1998 Jun; 351(9120):1929-30. PubMed ID: 9654265
    [No Abstract]   [Full Text] [Related]  

  • 9. Mibefradil: a new class of calcium-channel antagonists.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
    Brogden RN; Markham A
    Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure.
    Mulder P; Richard V; Compagnon P; Henry JP; Lallemand F; Clozel JP; Koen R; Macé B; Thuillez C
    J Am Coll Cardiol; 1997 Feb; 29(2):416-21. PubMed ID: 9014998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
    Massie BM
    Am J Hypertens; 1998 Apr; 11(4 Pt 3):95S-102S. PubMed ID: 9607373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mibefradil (posicor).
    Giles TD
    Compr Ther; 1997 Nov; 23(11):761-3. PubMed ID: 9360806
    [No Abstract]   [Full Text] [Related]  

  • 14. Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker.
    Clozel JP; Ertel EA; Ertel SI
    J Hypertens Suppl; 1997 Dec; 15(5):S17-25. PubMed ID: 9481612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD.
    Massie BM; Chrysant SG; Jain A; Weir M; Weiss R; Korrin I
    Clin Cardiol; 1997 Jun; 20(6):562-8. PubMed ID: 9181268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist.
    Abernethy DR
    Am J Cardiol; 1997 Aug; 80(4B):4C-11C. PubMed ID: 9286848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mibefradil, A T-type calcium channel antagonist in Y1 cells.
    Esneu M; Gallo-Payet N; Payet MD
    Endocr Res; 1998; 24(3-4):449-54. PubMed ID: 9888524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mibefradil release expands calcium-channel-blocker choices.
    Am J Health Syst Pharm; 1997 Sep; 54(18):2033. PubMed ID: 9377200
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
    Noll G; Lüscher TF
    Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists.
    Sarsero D; Fujiwara T; Molenaar P; Angus JA
    Br J Pharmacol; 1998 Sep; 125(1):109-19. PubMed ID: 9776350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.